BioAge Labs posts R&D Day presentation on BGE-102 program

PUBT·05/11/2026 17:10:53

Listen to the news

BioAge Labs published an R&D Day presentation highlighting Phase 1 results for lead program BGE-102, an oral brain-penetrant NLRP3 inhibitor positioned for cardiometabolic disease.
Presentation flagged 86% hsCRP reduction in obese subjects, with 87-93% achieving normalized hsCRP below 2 mg/L.
Program profile included 24-hour IL-1β suppression of at least 90% at 60 mg once daily, with CNS penetration reported at about 0.7 Kp,uu CSF at 120 mg multiple ascending dose on day 14.
Update outlined upcoming proof-of-concept readouts for cardiovascular risk in H2 2026, with diabetic macular edema proof-of-concept targeted for mid-2027.
Company also highlighted an APJ agonist obesity program, with IND submission targeted for year-end 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief on May 08, 2026, and is solely responsible for the information contained therein.

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Contact Number :+852 3852 8500

Monday 7:00 AM - Saturday 9:00 AM (HKT)

Service Email :service@webull.hk

Online Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)

Business Cooperation :marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English